Brent crude oil (ICE front-month) closes above $87.50 per barrel on July 22, 2026
Pending
✦ AI-generated prediction
Published on 19. July 2026
·
Predicted for 22. July 2026
·
Based on: Ongoing Event
Brent crude closed at approximately $88.10/bbl on Friday July 18, 2026 — already above the $87.50 threshold. Key drivers: US CENTCOM conducted strikes on Iranian infrastructure for 7 consecutive nights ending July 17; Iran is actively deploying Houthis to disrupt Red Sea shipping (Daily Caller, July 18). Houthi attacks already sank two vessels in July: Magic Seas (July 6, limpet mines) and Eternity C (July 9, crew taken hostage). On July 22 the ECB decision publishes — an expected hold at 2.25% provides no downward impulse for oil. Adjacent open predictions (Brent >$87.00 on July 21; Brent >$87.50 on July 23) are directionally consistent. No specific Polymarket market for July 22.
Data basis for this prediction
- Brent Crude: ~88,10 USD/Barrel am 18.07.2026 (Fortune / Trading Economics)
- CENTCOM: 7 Nächte Strikes auf Iran, Ende 17.07.2026 (centcom.mil / CNBC)
- Houthi versenkt Magic Seas (06.07.) und Eternity C (09.07.) im Roten Meer (Lloyd's List, Juli 2026)
- Iran rüstet Houthis für weitere Angriffe auf Schifffahrt (Daily Caller / BizPacReview, 18.07.2026)
Note: This is an AI-generated statistical forecast for entertainment and information purposes. It does not constitute investment advice or a recommendation to buy or sell any financial instrument.
Verdict: Pending
This prediction is still open. It will be evaluated automatically against real-world sources after its due date.
📈 Economy
✦ AI
Nestlé achieved organic growth of +3.5% in Q1 2026 (RIG +1.2%, pricing +2.3%) and reaffirmed full-year guidance of 3–4%. H1 2025 stood at +2.9%; momentum is improving, driven by Coffee (Nespresso) and emerging markets. Organic growth is FX-adjusted, so the ~−5% FX headwind is irrelevant here. Risk: consumer slowdown in Europe. No Polymarket contract found.
📈 Economy
✦ AI
AstraZeneca beat in Q1 2026 with core EPS of USD 2.58 vs. consensus USD 2.52 (+2.4%) and beat the revenue consensus at USD 15.29B (+13% YoY). Drivers: Oncology (Tagrisso, Imfinzi, Enhertu) and Rare Disease. H1 consensus is approx. USD 5.05; AZN has beaten EPS in each of the past six quarters. No Polymarket contract; calibrated from earnings-beat streak and pipeline strength.
📈 Economy
✦ AI
Bloomberg reported on 13 July 2026 that Shein targets up to USD 3B through a Hong Kong IPO in August 2026; valuation is below USD 50B (peak: USD 100B). The HKEX listing committee has completed its hearing; first public filings are expected from the week of 27 July. Headwinds: multiple prior IPO cancellations (UK, US 2023–2025), US import tariffs on Chinese e-commerce platforms, supply chain concerns. No Polymarket contract found.